Neuroblastoma: Recent Developments in Assessment and Management

  • J. Pritchard
  • J. Kemshead
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 88)


Not all children with neuroblastoma succumb to the disease. “Good-prognosis”, “intermediate-prognosis” and “bad-prognosis” patients can now be defined; unfortunately, the latter predominate and give the tumour its overall unsavoury reputation. Children with good-prognosis disease are often cured by surgery alone; by contrast there is little evidence to date of a fall in mortality for bad-prognosis patients. However, neuroblastoma is a chemoresponsive and radioresponsive tumour, and the “tail” on the survival curves published for several series of children treated with combination drug therapy indicate that, even for patients with advanced disease, cure is a less than remote possibility.


Total Body Irradiation High Dose Melphalan Vanillyl Mandelic Acid Good Partial Response Occult Tumour Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Evans AE, D’Angio GJ, Randolph J (1971) A proposed staging for children with neuroblastoma. Cancer 27: 374–378PubMedCrossRefGoogle Scholar
  2. 2.
    Evans AE, Baum E. Chard R (1981) Do infants with stage IVs neuroblastoma need treatment? Arch Dis Child 56: 271–274PubMedCrossRefGoogle Scholar
  3. 3.
    Finkelstein JZ, Klemperer M, Evans AE (1979) Multi-agent chemotherapy for children with metastatic neuroblastoma: a report from the Children’s Cancer Study Group. Med Pediatr Oncol 6: 179–188CrossRefGoogle Scholar
  4. 4.
    Gasparini M, Fossati-Bellani F, Musumeli R, Bonadonna G (1974) Response and survival of patients with metastatic neuroblastoma after combination therapy with adriamycin, cyclophosphamide and vincristine. Cancer Chemother Rep 58: 365–370PubMedGoogle Scholar
  5. 5.
    Goldman AJ, Vivian GC, Gordon I, Pritchard J, Kemshead JT Immunolocalisation of neuroblastoma using radiolabelled monoclonal antibodies. Proc Amer Soc Clin Oncol (Abstr C-271) 19: 70Google Scholar
  6. 6.
    Hayes FA, Green AA, Casper J, Cornet J, Evans WE (1981) Clinical evaluation of sequentially scheduled cisplatin and VM 26 in neuroblastoma. Cancer 48: 1715–1718PubMedCrossRefGoogle Scholar
  7. 7.
    Hill BT, Whelan RDH (1981) Assessment of the sensitivities of cultured human neuroblastoma cells to anti-tumour drugs. Pediatr Res 15: 1117–1122PubMedGoogle Scholar
  8. 8.
    Kemshead JT, Rembaum A, Ugelstad J (1982a) The potential use of monoclonal antibodies and microspheres containing magnetic compounds to remove neuroblastoma cells from bone marrow to be used in autologous transplantation programmes. Proc Am Soc Cancer Res Proc Am Soc Clin Oncol (Abstr C143 ) 23: 36Google Scholar
  9. 9.
    Kemshead JT, Goldman A, Fritschy J, Malpas JS, Pritchard J (1983) The use of panels of monoclonal antibodies in the differential diagnosis of neuroblastoma and lymphoblastic malignancy. Lancet 1 /8: 12–15PubMedCrossRefGoogle Scholar
  10. 10.
    Knudson AG, Meadows AT (1980) Regression of neuroblastoma IVs; a genetic hypothesis. N Engl J Med 302: 1254–1256PubMedCrossRefGoogle Scholar
  11. 11.
    Laug WE, Siegel SE, Shaw KNF, Larsding B, Baptiste J, Gutenstein M (1978) Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics 62: 77–82PubMedGoogle Scholar
  12. 12.
    Malpas JS, Kemshead JT, Pritchard J, Greaves MF (1982) Heterogeneity in cell surface antigens on human neuroblastoma cells. In: Proceedings of the XIIIth meeting of the International Society of Paediatric Oncology. Excerpta Medica, Amsterdam pp 90–94Google Scholar
  13. 13.
    Ninane J, Pritchard J, Malpas JS (1981) Chemotherapy of advanced neuroblastoma: does adriamycin contribute? Arch Dis Child 56: 544–548PubMedCrossRefGoogle Scholar
  14. 14.
    Ninane J, Pritchard J, Morris-Jones P, Mann JR, Malpas JS (1982) Stage II neuroblastoma: adverse prognostic significance of lymph node involvement. Arch Dis Child 57: 438–442PubMedCrossRefGoogle Scholar
  15. 15.
    Nitschke R, Cangir A, Crist W, Berry DH (1980) Intensive chemotherapy for metastatic neuroblastoma. Med Pediatr Oncol 8: 281–288PubMedCrossRefGoogle Scholar
  16. 16.
    Pritchard J, Shafford EA, Craft AE, McElwain TJ (1981) High doses melphalan (HDM) with autologous bone marrow (ABM) for advanced neuroblastoma. Proc Am Soc Clin Oncol (Abstr C 307 ) 22: 410Google Scholar
  17. 17.
    Pritchard J, McElwain TJ, Graham-Pole J (1982) High dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 45: 86–98PubMedCrossRefGoogle Scholar
  18. 18.
    Raaf JH, Cangir A, Luna M (1982) Induction of neuroblastoma maturation by a new chemotherapy protocol. Med Pediatr Oncol 10: 275–282PubMedCrossRefGoogle Scholar
  19. 19.
    Tiedemann K, Long RG, Pritchard J, Bloom SR (1981) Plasma vaso-active intestinal polypeptide and other regulatory peptides in children with neurogenic tumours. Eur J Pediatr 137: 147–150PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1983

Authors and Affiliations

  • J. Pritchard
    • 1
  • J. Kemshead
    • 2
  1. 1.Department of Haematology and OncologyHospital for Sick Children Institute of Child HealthLondonUK
  2. 2.Imperial Cancer Research Fund Paediatric Oncology LaboratoryInstitute of Child HealthLondonUK

Personalised recommendations